Longitudinal Gut Microbiota Dysbiosis Underlies Olanzapine-Induced Weight Gain

Can we manage gut microbiome imbalances in patients with bipolar disorder with pharmacotherapy?

INTRODUCTION

A novel new area of exploration in the treatment of bipolar disorder is the gut brain axis. Studies have shown significant differences between the gut microbiome in those with bipolar disorder and those without the illness, as well as documented microbiome changes associated with the effects of bipolar pharmacotherapy and targeted microbial interventions. Although we have evidence suggesting the bi-directional relationship between the gut microbiome and psychiatric disorders, we are still unable to utilize this understanding clinically.

AREAS COVERED

We need to better understand the factors that impact the microbiome in this illness and vice versa.

EXPERT OPINION

Additionally, changes in gut microbiome in bipolar disorder might be used for biomarker identification with a potential to help in diagnosis and monitoring of the condition. It is an important area for further research and may provide improved therapeutic outcomes.